Human-based tissue scaffolds, including a biological vascular graft to provide vascular access to end-stage renal disease patients who need hemodialys...
There’s no risk. Start your trial today to see profiles of Humacyte (NASDAQ:HUMA) plus 5056 other startups.
The Medtech Pro Platform has Expanded! Request Demo
Replay LSI2021 Emerging Medtech Summit Play Now
New 2021 Forecasts Released New Data
New 2021 Forecasts Released Learn More
Become a Medtech Market ProLearn More